CME Presentations
Rett Cases
Presentations
Strategies for Early Diagnosis and Treatment in Rett Syndrome
Speakers: David Lieberman, MD, PhD, Child NeurologistArthur Beisang, MD, Complex Care Pediatrician Duration: 45 minutes
Presented on: December 7, 2023
Applying Guideline-recommended Multidisciplinary Care and Evidence-based Agents for the Management of Rett Syndrome
Speakers: David Lieberman, MD, PhD, Child NeurologistArthur Beisang, MD, Complex Care Pediatrician Duration: 45 minutes
Presented on: December 7, 2023
Your Questions Answered: Integrating Guidelines and Evidence-based Treatment into the Management of Rett Syndrome
Speakers: David Lieberman, MD, PhD, Child NeurologistArthur Beisang, MD, Complex Care Pediatrician Duration: 30 minutes
Presented on: January 16, 2024
Speakers
David Lieberman, MD, PhD
David Lieberman, MD, PhD
Child Neurologist
David Lieberman, MD, PhD, is a child neurologist at Boston Children’s Hospital. Dr. Lieberman completed his medical and doctorate degrees in Neuroscience at Stanford University School of Medicine. He continued his training at Johns Hopkins University School of Medicine, completing an internship in Pediatrics and a residency in Pediatric Neurology. Dr. Lieberman remained at Johns Hopkins as faculty for a few years before moving back to the west coast to take a faculty position in the Neurosciences Department at UC San Diego. Dr. Lieberman moved to Boston in 2015 and now serves as the Director of the Comprehensive Rett Syndrome Program at Boston Children’s Hospital where he sees over 100 patients with Rett syndrome and Rett-related disorders each year.
Arthur Beisang, MD
Arthur Beisang, MD
Complex Care Pediatrician
Arthur (Art) Beisang, MD, has been a practicing pediatrician for 30 years. He has focused exclusively on Complex Care Pediatrics since moving to Gillette Children’s Specialty Health Care in 2006. Dr. Beisang was a founder of the Rett and Rett-Related Disorders Clinic at Gillette. He is currently the Clinic’s Co-Director and Co-director of the Aerodigestive Clinic. His clinical goal is to maintain the health of his neurologically complex patients, including managing all aspects of feeding, diagnosing distressing symptoms (including dysautonomia), and managing aspiration and drooling. Dr. Beisang has multiple publications with a focus on Rett syndrome and multiple patents on medical devices. He’s devoted his life to improving the lives of children diagnosed with a rare disease.
CME Information
Your Questions Answered: Integrating Guidelines and Evidence-based Treatment into the Management of Rett Syndrome
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD), and the International Rett Syndrome Foundation (IRSF)ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Acadia Pharmaceuticals Inc.DATE OF RELEASE/EXPIRATION
This activity was released on January 16, 2024, and is valid until January 16, 2025. Requests for credit must be made no later than January 16, 2025.TARGET AUDIENCE
The primary target audience for this activity are neurologists, pediatric neurologists, and geneticists. The secondary audience for this activity are pediatricians, developmental pediatricians, primary care providers, orthopedists, advanced practice PTs/OTs, nutritionists, and other HCPs caring for patients with Rett syndrome.STATEMENT OF NEED/PROGRAM OVERVIEW
Have lingering unanswered questions about Rett syndrome, its diagnosis, and appropriate treatment? Join us for a special “FAQ Spotlight” session designed to answer frequently asked clinician questions and provide updated information on the management of Rett syndrome. Join David Lieberman, MD, PhD and Arthur A. Beisang III, MD will lead the session based on questions gathered during previous CME activities on Rett Syndrome.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Share strategies to optimize the treatment of patients with Rett Syndrome
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation.
Instructions for Credit
Participation in this self-study activity should be completed in approximately 30 minutes. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from January 16, 2024 through January 16, 2025:- Review the objectives and disclosures
- Study the educational content
- Complete the activity evaluation
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.Name of Faculty or Presenter Conflicts of Interest David N. Lieberman, MD, PhD
Child Neurologist
Director, Comprehensive Rett Syndrome Clinic
Boston Children’s HospitalConsultant/Advisor/Speaker: Neurogene, Taysha Gene Therapies, Acadia Pharmaceuticals, Dewpoint Arthur A. Beisang III, MD
Complex Care Pediatrician
Co-Director, Rett and Rett Related Disorders Clinic
Gillette Children’sConsultant/Advisor/Speaker: Acadia DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD), and the International Rett Syndrome Foundation (IRSF)Applying Guideline-recommended Multidisciplinary Care and Evidence-based Agents for the Management of Rett Syndrome
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Acadia Pharmaceuticals Inc.DATE OF RELEASE/EXPIRATION
This activity was released on December 7, 2023 and is valid until January 16, 2025. Requests for credit must be made no later than January 16, 2025.TARGET AUDIENCE
The primary target audience for this activity are neurologists, pediatric neurologists, and geneticists. The secondary audience for this activity are pediatricians, developmental pediatricians, primary care providers, orthopedists, advanced practice PTs/OTs, nutritionists, and other HCPs caring for patients with Rett syndrome.STATEMENT OF NEED/PROGRAM OVERVIEW
A new treatment option for Rett syndrome is now available, creating an impetus for earlier diagnosis and improved awareness among clinicians about when and how approved agents should be integrated into treatment plans. Awareness of the basics of Rett syndrome, newly approved treatments, and multidisciplinary approaches to care can help reduce time to diagnosis, alleviate the burden of disease, and improve quality of life for both patients and caregivers.
Join David N. Lieberman, MD, PhD and Arthur A. Beisang III, MD to discuss treatment selection, integration of newly approved agents, and the place of multidisciplinary care in the evolving management of Rett syndrome. The panel will also discuss available options for managing symptoms of Rett syndrome (gastrointestinal dysfunction, epilepsy, and physical and communication deficits), along with solutions to manage adverse events associated with therapy.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Review the latest clinical evidence on new FDA-approved and emerging therapies for Rett syndrome
- Define the place in care of new treatment options in the multidisciplinary approach to Rett syndrome management
- Apply a team-based approach to the care of patients with Rett syndrome, including monitoring for and managing GI-related and other AEs associated with approved therapies
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PHYSICIAN CONTINUING EDUCATION
PACE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 45 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Faculty Conflicts of Interest David N. Lieberman, MD, PhD
Child Neurologist
Director, Comprehensive Rett Syndrome Clinic
Boston Children’s HospitalConsultant, Advisor, Speaker: Neurogene, Taysha Gene Therapies, Acadia Pharmaceuticals, Dewpoint Arthur A. Beisang III, MD
Complex Care Pediatrician
Co-Director, Rett and Rett Related Disorders Clinic
Gillette Children’sConsultant, Advisor, Speaker: Acadia Emily
Vignette Participant
Parent of a child with Rett syndromeNothing to disclose
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.Technical Support:
For any technical issues or issues with your CME Certificate, please contact NueroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD), and the International Rett Syndrome Foundation (IRSF)Strategies for Early Diagnosis and Treatment in Rett Syndrome
ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from Acadia Pharmaceuticals Inc.DATE OF RELEASE/EXPIRATION
This activity was released on December 7, 2023 and is valid until January 16, 2025. Requests for credit must be made no later than January 16, 2025.TARGET AUDIENCE
The primary target audience for this activity are neurologists, pediatric neurologists, and geneticists. The secondary audience for this activity are pediatricians, developmental pediatricians, primary care providers, orthopedists, advanced practice PTs/OTs, nutritionists, and other HCPs caring for patients with Rett syndrome.STATEMENT OF NEED/PROGRAM OVERVIEW
Individuals with Rett syndrome suffer from a wide array of symptoms and, during later stages of the disease, a variety of comorbidities occur that contribute to disease severity and affect patients’ ability to communicate and perform day-to-day tasks. Improving outcomes for these patients depends upon accurate and timely diagnoses and individualizing treatment based on each patient’s needs and comorbidities.
Join David Lieberman, MD, PhD and Arthur A. Beisang III, MD to discuss how to identify the early signs and symptoms of Rett syndrome, improve diagnoses, and recognize the role of genetic testing in diagnosis. Patient/caregiver video vignettes will be used to detail patient cases, providing clinicians with an opportunity to think through real-world case scenarios and implement best practices in Rett syndrome management.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Describe the physical and developmental signs and symptoms associated with each of the four stages of Rett syndrome to enhance timely and accurate diagnoses
- Integrate strategies to counsel patients/caregivers and manage expectations with new treatment options for Rett syndrome
- Select appropriate, evidence-based treatment options for patients with Rett syndrome
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PHYSICIAN CONTINUING EDUCATION
PACE designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 45 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Faculty Conflicts of Interest David N. Lieberman, MD, PhD
Child Neurologist
Director, Comprehensive Rett Syndrome Clinic
Boston Children’s HospitalConsultant, Advisor, Speaker: Neurogene, Taysha Gene Therapies, Acadia Pharmaceuticals, Dewpoint Arthur A. Beisang III, MD
Complex Care Pediatrician
Co-Director, Rett and Rett Related Disorders Clinic
Gillette Children’sConsultant, Advisor, Speaker: Acadia Megan Case
Vignette Participant
Parent and Caregiver of Child with Rett SyndromeNothing to disclose
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com.Technical Support:
For any technical issues or issues with your CME Certificate, please contact NueroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.
